Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands.
Am J Gastroenterol. 2012 Apr;107(4):534-42. doi: 10.1038/ajg.2011.459. Epub 2012 Jan 24.
OBJECTIVES: In patients with high-grade dysplasia (HGD) in Barrett's esophagus (BE), it is incompletely known which factors are associated with developing esophageal adenocarcinoma (EAC). We analyzed prior biopsy and follow-up strategies in a large nationwide population-based cohort of patients with HGD in BE, and identified predictors of EAC progression. METHODS: Prior biopsy records and follow-up evaluations were studied in patients with HGD in BE diagnosed between 1999 and 2008, using PALGA, a nationwide network and registry of histopathology and cytopathology in the Netherlands. Multivariate Cox proportional hazards regression analysis was performed to identify predictors for prevalent (≤ 6 months) and incident (> 6 months) EAC. RESULTS: In total, 827 patients with HGD in BE were included. Follow-up data after HGD diagnosis were available in 699 (85%) patients. In 249 (36%) of these patients, an EAC was detected (14.1 EACs per 100 person-years). The risk of prevalent EAC (n=177) was lower with previous surveillance (hazards ratio 0.7; 95% confidence interval 0.5-0.9), unifocal HGD (0.3;0.2-0.6), diagnosis in a university hospital (0.5;0.3-0.9), endoscopic resection (0.5;0.3-0.7), or ablation (0.0;0.0-0.3); and higher when patients were 65-75 years (1.5;1.04-2.04). After exclusion of prevalent EACs, the progression rate was 4.2 EACs per 100 person-years. The risk of progression to incident EAC (n = 72) was lower with previous surveillance (0.6;0.3-0.9) and ablation (0.2;0.0-0.8), and higher when > 75 years (3.8;2.0-7.2) or with an interval > 6 months between HGD diagnosis and first follow-up (e.g., 7-12 months 2.9;1.3-6.3). CONCLUSIONS: In this cohort of patients with HGD in BE, the EAC detection rate was 14.1 per 100 person-years and 4.2 per 100 person-years after excluding prevalent cases. The risk of both prevalent and incident EAC was reduced with previous surveillance and endoscopic treatment, while it was increased with older age.
目的:在 Barrett 食管(BE)中出现高级别异型增生(HGD)的患者中,尚不完全清楚哪些因素与食管腺癌(EAC)的发展相关。我们分析了大量 BE 中 HGD 患者的既往活检和随访策略,并确定了 EAC 进展的预测因素。
方法:通过荷兰全国性的组织病理学和细胞病理学网络和登记处 PALGA,研究了 1999 年至 2008 年间诊断为 BE 中 HGD 的患者的既往活检记录和随访评估。使用多变量 Cox 比例风险回归分析来确定 EAC 进展的预测因素(随访 6 个月内出现的 EAC 为现患性,随访 6 个月以上出现的 EAC 为新发性)。
结果:共纳入 827 例 BE 中 HGD 患者。在 699 例(85%)患者中可获得 HGD 诊断后的随访数据。在这些患者中,有 249 例(36%)检测到 EAC(每 100 人年 14.1 例)。现患性 EAC(n=177)的风险较低与先前的监测(风险比 0.7;95%置信区间 0.5-0.9)、单灶性 HGD(0.3;0.2-0.6)、在大学医院诊断(0.5;0.3-0.9)、内镜切除(0.5;0.3-0.7)或消融(0.0;0.0-0.3)有关;而患者年龄在 65-75 岁时风险较高(1.5;1.04-2.04)。排除现患性 EAC 后,进展率为每 100 人年 4.2 例。新发 EAC(n=72)进展的风险较低与先前的监测(0.6;0.3-0.9)和消融(0.2;0.0-0.8)有关,而年龄较高(>75 岁)或 HGD 诊断与首次随访之间的间隔较长(如 7-12 个月,2.9;1.3-6.3)时风险较高。
结论:在本队列中,BE 中 HGD 患者的 EAC 检出率为每 100 人年 14.1 例,排除现患性病例后为每 100 人年 4.2 例。现患性和新发性 EAC 的风险均随先前的监测和内镜治疗而降低,而随年龄增长而增加。
Am J Gastroenterol. 2011-5-17
Gastroenterology. 2011-6-30
Dis Esophagus. 2017-3-1
Clin Gastroenterol Hepatol. 2006-5